| 5JLJ: reference: Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies., Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman AM, Lucas DM, Baloglu E, Shacham S, Kauffman MG, Byrd JC, Chook YM, Garzon R, Lapalombella R, Leukemia. 2016 Jun 21. doi: 10.1038/leu.2016.136. PMID: 27323910 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).